KELLIE KOZAK: Open Payments
NPI 1255716825 · VOORHEES, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$730 in 50 payments from 10 companies in 2025. Trend: 2023 $504 · 2024 $189 · 2025 $730
Food & beverage: $674Education: $56
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 11 | $233 |
| GlaxoSmithKline, LLC. | 21 | $150 |
| ARS Pharmaceuticals Operations, Inc. | 5 | $92 |
| Genentech USA, Inc. | 4 | $65 |
| SANOFI-AVENTIS U.S. LLC | 1 | $56 |
| Amgen Inc. | 3 | $47 |
| Optinose US, Inc. | 2 | $28 |
| ALK-Abello, Inc | 1 | $27 |
| AstraZeneca Pharmaceuticals LP | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $16 |
Products named: DUPIXENT, NUCALA, NEFFY, Xolair, TEZSPIRE, Xhance, Grastek, Ryaltris.
Industry payments across NJ — which companies pay providers there.
